Veterans with KRAS G12C-Mutated NSCLC TheKRASG12C inhibitor sotorasib was approved for treating advanced NSCLC in the second line or later on the basis of the CodeBreaK100 trial. Nevertheless, ... KI Zhou,C Lin,CL Tseng,... - 《Jto Clinical & Research Reports》 被引量: 0发表: 2024...
S. Skoulidis, B.T. Li, G.K. Dy, et al. Sotorasib for Lung Cancers with KRAS p. G12C Mutation N Engl J Med, 384 (25) (2021), pp. 2371-2381, 10.1056/NEJMoa2103695 View in ScopusGoogle Scholar [25] https://www.evaluate.com/vantage/articles/news/trial-results/amgens-low-dose...
demonstrated that the prognosis of patients having surgery for early-stage NS-NSCLC showing a KRAS G12C mutation had more recurrence than in cases of other KRAS mutation subtypes or KRAS wild-type tumors, thus opening the door in the future for potential adjuvant therapy targeting KRAS G12C [...
KRAS tumor mutations were detected in about 35% of patients; about 65% of patients had KRAS wild type tumors. KRAS mutation in colon ca blocks Cetuximab ELI-002 is an "AMP KRAS vaccine" containing seven Amphiphile mKRAS peptides and a proprietary Amphiphile adjuvant, administered subcutaneously....
KRAS p.G13D c.38G>A NM_033360.2 14.0% 2526 KRAS p.G12D c.35G>A NM_033360.2 5.3% 2533 BRCA2 p.K1691Nfs*15 c.5073delA NM_000059.3 31.7% 2118 BRCA2 p.N1784Tfs*7 c.5351delA NM_000059.3 35.5% 1989 BRCA2 p.I2675Dfs*6 c.8021dupA NM_000059.3 8.2% 2451 BRCA1 p.R1443* c....
CD90+ CAFs promotes tumor cell inva- sion by enhancing tumor cell–endothelial cell attachment in a KrasG12D-driven LUAC (KrasLA1) mouse model [159]. In hepatocellular carcinoma (HCC), a significant number of CAFs highly express CD90, which correlates with angiogenesis markers (CD105, ...
0:08 |Sunitinib has activity against primaryKITmutations. It also has activity against some of the secondaryKITmutations. To explain a little bit about the mutations, there are 2 major mutations that we identify in tumors in GIST. When it's aKITmut...
To circumvent resistance mechanisms, researchers have investigated another mutation that leads to resistance to kinase inhibitors. RAS mutations, mainly HRAS and KRAS, lead to approximately 40% of sporadic MTC cases without RET mutations [115]. The remaining 20% of cases have no identified oncogenic...
[3]. Considering NSCLC, at the time of diagnosis, all advanced non-squamous NSCLC should be screened for EGFR (exon 18: G719x; exon 19: ex19del; exon 20: T790M, S768I, ex20ins; exon 21: L858R, L861Q), KRAS (G12C), BRAF (V600E), and HER2 mutations, for MET exon 14 ...